Primary Versus Secondary Failure After Varicella Vaccination: Implications for Interval Between 2 Doses

Pediatric Infectious Disease Journal

Volumn 32, Issue 7, 2013, Pages e305-e313

  Bonanni, Paolo ^a   Gershon, Anne ^a   Gershon, Michael ^a   Kulcsár, Andrea ^a   Papaevangelou, Vassiliki ^a   Rentier, Bernard ^a   Sadzot Delvaux, Catherine ^a   Usonis, Vytautas ^a   Vesikari, Timo ^a   Weil Olivier, Catherine ^a   de Winter, Peter ^a   Wutzler, Peter ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Dose interval; Vaccine failure; Varicella vaccination

Indexed keywords

CHICKENPOX VACCINE; PLACEBO; VARICELLA ZOSTER VACCINE;

AGE DISTRIBUTION; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; ASTHMA; CELLULAR IMMUNITY; CHICKENPOX; ECZEMA; EPIDEMIC; HUMAN; IMMUNOGENICITY; META ANALYSIS; PRIORITY JOURNAL; PUBLICATION; RECOMMENDED DRUG DOSE; SEROCONVERSION; SYSTEMATIC REVIEW; VACCINATION; VACCINE FAILURE;

CHICKENPOX; CHICKENPOX VACCINE; HUMANS; TIME FACTORS; TREATMENT FAILURE; VACCINATION;

EID: 84883207797     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31828b7def     Document Type: Article

References (100)

1. Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med. 2005;352:450-458
2. Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA. 2002;287:606-611
3. Shah SS, Wood SM, Luan X, et al. Decline in varicella-related ambulatory visits and hospitalizations in the United States since routine immunization against varicella. Pediatr Infect Dis J. 2010;29:199-204
4. Siedler A, Arndt U. Impact of the routine varicella vaccination programme on varicella epidemiology in Germany. Euro Surveill. 2010;15:19530
5. Giammanco G, Ciriminna S, Barberi I, et al. Universal varicella vaccination in the Sicilian paediatric population: rapid uptake of the vaccination programme and morbidity trends over five years. Euro Surveill. 2009;14:19321
6. Spackova M, Muehlen M, Siedler A. Complications of varicella after implementation of routine childhood varicella vaccination in Germany. Pediatr Infect Dis J. 2010;29:884-886
7. Quian J, Rüttimann R, Romero C, et al. Impact of universal varicella vaccination on 1-year-olds in Uruguay: 1997-2005. Arch Dis Child. 2008;93:845-850
8. Pozza F, Piovesan C, Russo F, et al. Impact of universal vaccination on the epidemiology of varicella in Veneto, Italy. Vaccine. 2011;29:9480-9487
9. Seward JF, Marin M, Vázquez M. Varicella vaccine effectiveness in the US vaccination program: a review. J Infect Dis. 2008;197(suppl 2):S82-S89
10. Chaves SS, Gargiullo P, Zhang JX, et al. Loss of vaccine-induced immunity to varicella over time. N Engl J Med. 2007;356:1121-1129
11. Gershon AA, Katz SL. Perspective on live varicella vaccine. J Infect Dis. 2008;197(suppl 2):S242-S245
12. Shapiro ED, Vazquez M, Esposito D, et al. Effectiveness of 2 doses of varicella vaccine in children. J Infect Dis. 2011;203:312-315
13. Arnedo-Pena A, Puig-Barberà J, Aznar-Orenga MA, et al. Varicella vaccine effectiveness during an outbreak in a partially vaccinated population in Spain. Pediatr Infect Dis J. 2006;25:774-778
14. Bayer O, Heininger U, Heiligensetzer C, et al. Metaanalysis of vaccine effectiveness in varicella outbreaks. Vaccine. 2007;25:6655-6660
15. Buchholz U, Moolenaar R, Peterson C, et al. Varicella outbreaks after vaccine licensure: should they make you chicken? Pediatrics. 1999;104(3 Pt 1):561-563
16. Centers for Disease Control and Prevention. Outbreak of varicella among vaccinated children-Michigan, 2003. MMWR Morb Mortal Wkly Rep. 2004;53:389-392
17. Centers for Disease Control and Prevention. Varicella outbreak among vaccinated children-Nebraska, 2004. MMWR Morb Mortal Wkly Rep. 2006;55:749-752
18. Dworkin MS, Jennings CE, Roth-Thomas J, et al. An Outbreak of Varicella among children attending preschool and elementary school in Illinois. Clin Infect Dis. 2002;35:102-104
19. Galil K, Fair E, Mountcastle N, et al. Younger age at vaccination may increase risk of varicella vaccine failure. J Infect Dis. 2002;186:102-105
20. Galil K, Lee B, Strine T, et al. Outbreak of varicella at a day-care center despite vaccination. N Engl J Med. 2002;347:1909-1915
21. Gould PL, Leung J, Scott C, et al. An outbreak of varicella in elementary school children with two-dose varicella vaccine recipients-Arkansas, 2006. Pediatr Infect Dis J. 2009;28:678-681
22. Haddad MB, Hill MB, Pavia AT, et al. Vaccine effectiveness during a varicella outbreak among schoolchildren: Utah, 2002-2003. Pediatrics. 2005;115:1488-1493
23. Izurieta HS, Strebel PM, Blake PA. Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center. JAMA. 1997;278:1495-1499
24. Lai CC, Chen SC, Jiang DD. An outbreak of varicella among schoolchildren in Taipei. BMC Public Health. 2011;11:226
25. Lee BR, Feaver SL, Miller CA, et al. An elementary school outbreak of varicella attributed to vaccine failure: policy implications. J Infect Dis. 2004;190:477-483
26. Lopez AS, Guris D, Zimmerman L, et al. One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose? Pediatrics. 2006;117:e1070-e1077
27. Marin M, Nguyen HQ, Keen J, et al. Importance of catch-up vaccination: experience from a varicella outbreak, Maine, 2002-2003. Pediatrics. 2005;115:900-905
28. Miron D, Lavi I, Kitov R, et al. Vaccine effectiveness and severity of varicella among previously vaccinated children during outbreaks in day-care centers with low vaccination coverage. Pediatr Infect Dis J. 2005;24:233-236
29. Parker AA, Reynolds MA, Leung J, et al. Challenges to implementing second-dose varicella vaccination during an outbreak in the absence of a routine 2-dose vaccination requirement-Maine, 2006. J Infect Dis. 2008;197(suppl 2):S101-S107
30. Spackova M, Wiese-Posselt M, Dehnert M, et al. Comparative varicella vaccine effectiveness during outbreaks in day-care centres. Vaccine. 2010;28:686-691
31. Tafuri S, Martinelli D, De Palma M, et al. Report of varicella outbreak in a low vaccination coverage group of otherwise healthy children in Italy: the role of breakthrough and the need of a second dose of vaccine. Vaccine. 2010;28:1594-1597
32. Tugwell BD, Lee LE, Gillette H, et al. Chickenpox outbreak in a highly vaccinated school population. Pediatrics. 2004;113(3 Pt 1):455-459
33. Centers for Disease Control and Prevention. Public health response to varicella outbreaks-United States, 2003-2004. MMWR Morb Mortal Wkly Rep. 2006;55:993-995
34. Vázquez M, LaRussa PS, Gershon AA, et al. Effectiveness over time of varicella vaccine. JAMA. 2004;291:851-855
35. Vázquez M, LaRussa PS, Gershon AA, et al. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med. 2001;344:955-960
36. Passwell JH, Hemo B, Levi Y, et al. Use of a computerized database to study the effectiveness of an attenuated varicella vaccine. Pediatr Infect Dis J. 2004;23:221-226
37. Sheffer R, Segal D, Rahamani S, et al. Effectiveness of the Oka/GSK attenuated varicella vaccine for the prevention of chickenpox in clinical practice in Israel. Pediatr Infect Dis J. 2005;24:434-437
38. Huang WC, Huang LM, Chang IS, et al. Varicella breakthrough infection and vaccine effectiveness in Taiwan. Vaccine. 2011;29:2756-2760
39. Hirose M, Hidaka Y, Miyazaki C, et al. Five cases of measles secondary vaccine failure with confirmed seroconversion after live measles vaccination. Scand J Infect Dis. 1997;29:187-190
40. Varis T, Vesikari T. Efficacy of high-titer live attenuated varicella vaccine in healthy young children. J Infect Dis. 1996;174(suppl 3):S330-S334
41. Black S, Ray P, Shinefield H, et al. Lack of association between age at varicella vaccination and risk of breakthrough varicella, within the Northern California Kaiser Permanente Medical Care Program. J Infect Dis. 2008;197(suppl 2):S139-S142
42. Verstraeten T, Jumaan AO, Mullooly JP, et al.Vaccine Safety Datalink Research Group. A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination. Pediatrics. 2003;112:e98-103
43. Lee LE, Ho H, Lorber E, et al. Vaccine-era varicella epidemiology and vaccine effectiveness in a public elementary school population, 2002-2007. Pediatrics. 2008;121:e1548-e1554
44. Kurugol Z, Halicioglu O, Koc F, et al. Varicella rates among unvaccinated and one-dose vaccinated healthy children in Izmir, Turkey. Int J Infect Dis. 2011;15:e475-e480
45. Barzaga NG, Florese RH, Bock HL. Reactogenicity and immunogenicity of a varicella vaccine in healthy seronegative and seropositive subjects. Southeast Asian J Trop Med Public Health. 2002;33:259-267
46. Clements DA, Armstrong CB, Ursano AM, et al. Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescents. Pediatr Infect Dis J. 1995;14:874-879
47. Gatchalian S, Tabora C, Bermal N, et al. Immunogenicity and safety of a varicella vaccine (Okavax) and a trivalent measles, mumps, and rubella vaccine (Trimovax) administered concomitantly in healthy Filipino children 12-24 months old. Am J Trop Med Hyg. 2004;70:273-277
48. Gillet Y, Habermehl P, Thomas S, et al. Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro) and a varicella vaccine (VARIVAX) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial. BMC Med. 2009;7:16
49. Gillet Y, Steri GC, Behre U, et al. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine. Vaccine. 2009;27:446-453
50. Johnson CE, Stancin T, Fattlar D, et al. A long-term prospective study of varicella vaccine in healthy children. Pediatrics. 1997;100:761-766
51. Kanra G, Ceyhan M, Ozmert E. Safety and immunogenicity of live attenuated varicella vaccine in 9-month-old children. Pediatr Int. 2000;42:674-677
52. Kim SH, Lee HJ, Park SE, et al. Seroprevalence rate after one dose of varicella vaccine in infants. J Infect. 2010;61:66-72
53. Li S, Chan IS, Matthews H, et al. Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection. Pediatr Infect Dis J. 2002;21:337-342
54. Lim YJ, Chew FT, Tan AY, et al. Risk factors for breakthrough varicella in healthy children. Arch Dis Child. 1998;79:478-480
55. Merck. Package circular for VARIVAX™ (Varicella Virus Vaccine Live) 2001. Available at: http://www.merck.com/product/usa/pi_circulars/v/varivax/varivax_pi.pdf. Accessed January 12, 2013
56. Meurice F, De Bouver JL, Vandevoorde D, et al. Immunogenicity and safety of a live attenuated varicella vaccine (Oka/SB Bio) in healthy children. J Infect Dis. 1996;174(suppl 3):S324-S329
57. Michalik DE, Steinberg SP, Larussa PS, et al. Primary vaccine failure after 1 dose of varicella vaccine in healthy children. J Infect Dis. 2008;197:944-949
58. Ngai AL, Staehle BO, Kuter BJ, et al. Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children. Pediatr Infect Dis J. 1996;15:49-54
59. Nolan T, Bernstein DI, Block SL, et al.LAIV Study Group. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age. Pediatrics. 2008;121:508-516
60. Nolan T, McIntyre P, Roberton D, et al. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine. Vaccine. 2002;21:281-289
61. Ramkissoon A, Coovadia HM, Jugnundan P, et al. Immunogenicity and safety of a live attenuated varicella vaccine in healthy Indian children aged 9-24 months. S Afr Med J. 1995;85:1295-1298
62. Rümke HC, Loch HP, Hoppenbrouwers K, et al. Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses. Vaccine. 2011;29:3842-3849
63. Schuster V, Otto W, Maurer L, et al. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. Pediatr Infect Dis J. 2008;27:724-730
64. Shinefield H, Black S, Digilio L, et al. Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J. 2005;24:665-669
65. Shinefield H, Black S, Williams WR, et al.Dose Selection Study Group for Proquad. Dose-response study of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J. 2005;24:670-675
66. Shinefield HR, Black SB, Staehle BO, et al.Kaiser Permanente Medical Team for Varivax. Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children. Pediatr Infect Dis J. 2002;21:555-561
67. Silber JL, Chan IS, Wang WW, et al. Immunogenicity of Oka/Merck varicella vaccine in children vaccinated at 12-14 months of age versus 15-23 months of age. Pediatr Infect Dis J. 2007;26:572-576
68. Stück B, Stehr K, Bock HL. Concomitant administration of varicella vaccine with combined measles, mumps, and rubella vaccine in healthy children aged 12 to 24 months of age. Asian Pac J Allergy Immunol. 2002;20:113-120
69. Tan AY, Connett CJ, Connett GJ, et al. Use of a reformulated Oka strain varicella vaccine (SmithKline Beecham Biologicals/Oka) in healthy children. Eur J Pediatr. 1996;155:706-711
70. Vessey SJ, Chan CY, Kuter BJ, et al. Childhood vaccination against varicella: persistence of antibody, duration of protection, and vaccine efficacy. J Pediatr. 2001;139:297-304
71. Watson B, Rothstein E, Bernstein H, et al. Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization. J Infect Dis. 1995;172:217-219
72. Watson BM, Laufer DS, Kuter BJ, et al. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children. J Infect Dis. 1996;173:731-734
73. Ampofo K, Saiman L, LaRussa P, et al. Persistence of immunity to live attenuated varicella vaccine in healthy adults. Clin Infect Dis. 2002;34:774-779
74. Saiman L, LaRussa P, Steinberg SP, et al. Persistence of immunity to varicella-zoster virus after vaccination of healthcare workers. Infect Control Hosp Epidemiol. 2001;22:279-283
75. Arvin A, Gershon A. Control of varicella: why is a two-dose schedule necessary? Pediatr Infect Dis J. 2006;25:475-476
76. Watson B, Boardman C, Laufer D, et al. Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine. Clin Infect Dis. 1995;20:316-319
77. Ludwig B, Kraus FB, Allwinn R, et al. Loss of varicella zoster virus antibodies despite detectable cell mediated immunity after vaccination. Infection. 2006;34:222-226
78. Amanna IJ, Messaoudi I, Slifka MK. Protective immunity following vaccination: how is it defined? Hum Vaccin. 2008;4:316-319
79. Fu C, Wang M, Liang J, et al. The effectiveness of varicella vaccine in China. Pediatr Infect Dis J. 2010;29:690-693
80. Tseng HF, Tan HF, Chang CK. Varicella vaccine safety, incidence of breakthrough, and factors associated with breakthrough in Taiwan. Am J Infect Control. 2003;31:151-156
81. Ozaki T, Nishimura N, Kajita Y. Experience with live attenuated varicella vaccine (Oka strain) in healthy Japanese subjects; 10-year survey at pediatric clinic. Vaccine. 2000;18:2375-2380
82. Takayama N, Minamitani M, Takayama M. High incidence of breakthrough varicella observed in healthy Japanese children immunized with live attenuated varicella vaccine (Oka strain). Acta Paediatr Jpn. 1997;39:663-668
83. Brisson M, Edmunds WJ, Gay NJ, et al. Analysis of varicella vaccine breakthrough rates: implications for the effectiveness of immunisation programmes. Vaccine. 2000;18:2775-2778
84. White CJ, Kuter BJ, Ngai A, et al. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr Infect Dis J. 1992;11:19-23
85. Kosuwon P, Sutra S, Kosalaraksa P. Advantage of a two-dose versus one-dose varicella vaccine in healthy non-immune teenagers and young adults. Southeast Asian J Trop Med Public Health. 2004;35:697-701
86. Czajka H, Schuster V, Zepp F, et al. A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): immunogenicity and safety profile. Vaccine. 2009;27:6504-6511
87. Goh P, Lim FS, Han HH, et al. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age. Infection. 2007;35:326-333
88. Halperin SA, Ferrera G, Scheifele D, et al. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age. Vaccine. 2009;27:2701-2706
89. Knuf M, Habermehl P, Zepp F, et al. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. Pediatr Infect Dis J. 2006;25:12-18
90. Kuter B, Matthews H, Shinefield H, et al.Study Group for Varivax. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J. 2004;23:132-137
91. Reisinger KS, Brown ML, Xu J, et al.Protocol 014 Study Group for ProQuad. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax. Pediatrics. 2006;117:265-272
92. Vesikari T, Baer M, Willems P. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years. Pediatr Infect Dis J. 2007;26:153-158
93. GlaxoSmithKline. GlaxoSmithKline clinical trial register: 104020 (MeMuRu-OKA-043). Available at: http://www.gsk-clinicalstudyregister.com/. Accessed 1
94. Wutzler P, Knuf M, Liese J. Varicella: efficacy of two-dose vaccination in childhood. Dtsch Arztebl Int. 2008;105:567-572
95. Kuter BJ, Ngai A, Patterson CM, et al. Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax) in healthy adolescents and adults. Oka/Merck Varicella Vaccine Study Group. Vaccine. 1995;13:967-972
96. Wiese-Posselt M, Hellenbrand W. Changes to the varicella and pertussis immunisation schedule in Germany 2009: background, rationale and implementation. Euro Surveill. 2010;15:19548
97. Marin M, Broder KR, Temte JL, et al.Centers for Disease Control and Prevention (CDC). Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(RR-3):1-12
98. Marin M, Güris D, Chaves SS, et al.Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC). Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-4):1-40
99. Nguyen MD, Perella D, Watson B, et al. Incremental effectiveness of second dose varicella vaccination for outbreak control at an elementary school in Philadelphia, pennsylvania, 2006. Pediatr Infect Dis J. 2010;29:685-689
100. Gershon AA. Varicella vaccine-are two doses better than one? N Engl J Med. 2002;347:1962-1963